Evaluation and validation of multiple potential biomarkers simultaneously
The use of informative biomarkers as predictive tools in clinical trials facilitates better use of resources and the potential discovery of new targeted medicines, with the aid of companion diagnostics.
The most sensitive, specific and selective biomarker tests available are immunoassays. NALIA's multiplex immunoassay system enables the evaluation and validation of multiple potential biomarkers simultaneously and using minimal sample quantities. Each NALIA Array replaces several existing single biomarker assays, miniaturising them and extending the scope of information available. This will enable clinicians to improve the diagnosis of complex diseases without increasing healthcare costs.
Key benefits of NALIA Arrays are:
Contact us for more information
Copyright © 2021 Nalia Systems Ltd. All rights reserved.
Registered company number: 05428896. Registered company address: Maven Accounting & Bookkeeping Ltd Sandgate, Netton Street, Salisbury, United Kingdom, SP5 4DF